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Abstract  16 
!17 
Human visceral leishmaniasis (VL) vaccines are currently under development and there is a 18 
need to understand their potential impact on population wide VL incidence.!We implement 19 
four characteristics from different human VL vaccine candidates into two published VL 20 
transmission model variants to estimate the potential impact of these vaccine characteristics 21 
on population-wide anthroponotic VL incidence on the Indian subcontinent (ISC). The 22 
vaccines that are simulated in this study 1) reduce the infectiousness of infected individuals 23 
towards sand flies, 2) reduce risk of developing symptoms after infection, 3) reduce the risk 24 
of developing post-kala-azar dermal leishmaniasis (PKDL), or 4) lead to the development of 25 
transient immunity. We also compare and combine a vaccine strategy with current 26 
interventions to identify their potential role in elimination of VL as a public health problem. 27 
We show that the first two simulated vaccine characteristics can greatly reduce VL incidence. 28 
For these vaccines, an approximate 60% vaccine efficacy would lead to achieving the ISC 29 
elimination target (<1 VL case per 10,000 population per year) within 10 years’ time in a 30 
moderately endemic setting when vaccinating 100% of the population. Vaccinating VL cases 31 
to prevent the development of PKDL is a promising tool to sustain the low incidence 32 
elimination target after regular interventions are halted. Vaccines triggering the development 33 
of transient immunity protecting against infection lead to the biggest reduction in VL 34 
incidence, but booster doses are required to achieve perduring impact.!Even though vaccines 35 
are not yet available for implementation, their development should be pursued as their 36 
potential impact on transmission can be substantial, both in decreasing incidence at the 37 
population level as well as in sustaining the ISC elimination target when other interventions 38 
are halted.  39 
  40 
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Author summary 41 
Vaccines for human visceral leishmaniasis (VL) are currently under development. In this 42 
study, we simulate VL transmission dynamics using mathematical models to explore the 43 
potential impact of vaccines on population-wide incidence. We show that some vaccines have 44 
high potential to reduce VL incidence, namely those that reduce the infectiousness of infected 45 
individuals to sand flies and those that reduce the chance of developing symptoms once 46 
infected. The effect of vaccines that lead to protection from infection is potentially the 47 
greatest, but depending on the duration of immunity, individuals would require booster doses 48 
to guarantee lifelong impact. Vaccines that prevent the development of post-kala-azar dermal 49 
leishmaniasis are a promising tool to sustain low VL incidence and prevent recrudescence of 50 
infection when regular interventions are halted. Our results strongly support the continued 51 
development of VL vaccines, as their potential impact on population incidence can be 52 
substantial. 53 
 54 
  55 
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Introduction 56 
!57 
Visceral leishmaniasis (VL), also known as kala-azar, is a vector-borne neglected tropical 58 
disease. Infection occurs after successful transmission of the Leishmania protozoa through 59 
the bite of an infected female sand fly [1]. Most infected humans remain asymptomatic, and 60 
only a small proportion of about 1—10% develop clinical symptoms, resulting in death when 61 
left untreated [2,3]. Between 5% and 20% of treated VL cases develop a long-lasting skin 62 
condition known as post-kala-azar dermal leishmaniasis (PKDL). Recent studies have 63 
identified that individuals with PKDL are equally infectious towards sand flies as VL cases, 64 
making them an important reservoir of infection [4,5]. However, the contribution of 65 
asymptomatic individuals to transmission has not yet been defined [4,6]. After infection, a 66 
period of immunity follows, of which the duration remains debated.  67 
 68 
Currently around 33,000—66,000 individuals develop symptomatic VL each year, mainly on 69 
the Indian subcontinent (ISC), Eastern Africa, the Mediterranean region, and Brazil, affecting 70 
the poorest of the poor [7,8] . The World Health Organization (WHO) and affected countries 71 
target for ‘elimination of VL as a public health problem by 2020’ on the ISC, where VL is 72 
considered to be solely anthroponotic. This target is defined as maintaining less than 1 VL 73 
case per 10,000 individuals per year at district level in Nepal, at subdistrict/block level in 74 
India, and at upazila level in Bangladesh [9]. In the rest of the world (e.g Africa, Europe, 75 
Brazil), where VL can also be zoonotic with the main reservoir of infection in dogs, the target 76 
is 100% detection and treatment of symptomatic cases [10]. Current strategies consist of 77 
diagnosis and treatment of VL cases, and vector control.  78 
 79 
Vaccines already play an important role in the control of canine leishmaniasis, at the 80 
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individual level they reduce the development of symptoms, reduce the parasite load in the 81 
blood, and reduce the risk of death [11–13]. These vaccines have also proven to be effective 82 
at the population level by reducing Leishmania transmission, resulting in lower incidence in 83 
both dogs and humans [14,15]. The development of human VL vaccines has been on-going 84 
for decades and there are different vaccine candidates currently in trial, but none are yet 85 
available for implementation [16,17]. The promising results from experimental human VL 86 
vaccine trials, and by the practice of “leishmanization”, in which a healthy individual is 87 
artificially exposed to tissue scrapings derived from a cutaneous leishmaniasis patient, 88 
leading to disease prevention [6,16,18–20], provide strong evidence for the scientific 89 
feasibility of an effective vaccine against human VL. Should an effective vaccine become 90 
available, it has been estimated to be cost-effective when used at large scale and in addition 91 
to ongoing diagnosis and treatment, without even accounting for its impact on transmission 92 
[19]. 93 
 94 
Mathematical transmission models are useful tools to gain insight into the effect of current 95 
and future interventions on VL incidence and the underlying transmission dynamics. 96 
Previous modelling studies that focused on VL transmission on the ISC presented two model 97 
variants; one in which only VL and PKDL cases contribute to transmission, and another in 98 
which also asymptomatic individuals contribute to transmission (~1% relative to VL cases). 99 
The models estimated that in most situations on the ISC, the target is likely to be met with 100 
current strategies but in high endemic settings and at a lower geographical scale, additional 101 
efforts are required. They also highlighted the risk of recrudescence of infection after 102 
achieving the low incidence target, when halting interventions. This is mainly due to 103 
individuals with PKDL and/or asymptomatic infection. Therefore, the studies emphasized the 104 
need for further research on the potential impact of preventive VL and PKDL strategies as a 105 
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tool in reaching and sustaining VL elimination as a public health problem on the ISC 106 
[5,21,22]. Other studies stressed that 100% detection and treatment of cases in the rest of the 107 
world remains challenging and that prevention could be much more effective than case 108 
detection and treatment [23]. 109 
 110 
In this study, we implement multiple characteristics of potential human VL vaccines using 111 
the two variants of a deterministic VL transmission model [21] to estimate the potential 112 
impact of these vaccine characteristics on VL incidence and transmission dynamics during 113 
and after the achievement of the current elimination target. The vaccines that are simulated in 114 
this study 1) reduce the infectiousness of infected individuals towards the sand fly, 2) reduce 115 
the risk of developing symptoms after infection, 3) reduce the risk of development of PKDL, 116 
or 4) lead to the development of transient immunity to infection [24–26]. We also compare 117 
and combine vaccine characteristics with current interventions to identify which vaccines 118 
could be most impactful in fighting this neglected tropical disease.  119 
 120 
 121 
Methods 122 
Overview of VL vaccine candidates and characteristics 123 
Currently there are various VL vaccine candidates under study [27]: LEISH-F3+GLA-SE 124 
[28,29], and ChAd63-KH (ISRCTN07766359) [30] are currently in clinical development; 125 
Ad5-A2/rA2 Prime / Boost [31], genetically modified live attenuated whole parasites 126 
[25,26,32], and a LmCen-/- vaccine [33] are being developed for the clinic [34]. 127 
 128 
These vaccines have different physical and immunological properties, and could be used in 129 
either prophylactic or therapeutic settings, but their impact following infected sand fly bite in 130 
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humans has yet to be evaluated. Table 1 summarizes different potential vaccine outcome 131 
measures (herein called characteristics) that were selected for simulation in this study. 132 
Vaccine characteristic 1 is separated into 1a) asymptomatic individuals and 1b) all infected 133 
individuals, because it is suggested that only individuals with asymptomatic infection may be 134 
affected by the vaccine and that once an individual develops symptoms there are no 135 
differences in infectiveness (1a). However, since this is not yet well established, we also 136 
include the option where all infected individuals become less infective, as a result of the 137 
vaccine (1b).  138 
Table 1. Human VL vaccine characteristics. 139 
Number Vaccine characteristic 
1a Reduced infectivity of asymptomatic individuals  
1b Reduced infectivity of all infected individuals 
2 Reduced risk of developing symptoms 
3 Reduced risk of developing PKDL 
4 Development of transient immunity protecting against infection 
 140 
Transmission models and simulation of existing interventions 141 
Fig 1 illustrates the basic structure of the VL transmission model, which is a deterministic 142 
age-structured model. There are two model variants, that only differ based on assumptions 143 
about where the main reservoir of infection lies; namely, solely in symptomatic individuals 144 
(VL and PKDL), or mainly in asymptomatic individuals [21,35,36]. The models were 145 
parameterized with age-structured data on approximately 21,000 individuals included in the 146 
KalaNet bednet trial in India and Nepal [37] and have undergone geographical cross-147 
validation against data on >5000 VL cases from 8 endemic districts in Bihar collected by 148 
CARE India [38] (see [36] for full model code and descriptions, and sensitivity analyses). 149 
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Recent outcomes from xenodiagnosis studies have been incorporated, indicating that those 150 
with PKDL are on average nearly as infectious as those with VL (0.9:1.0) [4,5]. 151 
 152 
Interventions of which the effects have previously been modelled are vector control through 153 
indoor-residual spraying of insecticide (IRS) and active case detection (ACD). The 154 
guidelines, as developed by WHO, recommend a 5-year attack phase (intense IRS and ACD) 155 
followed by 5 years of consolidation phase (IRS and intense ACD). In our models, IRS leads 156 
to a decrease in sand fly density and ACD shortens the duration of the symptomatic untreated 157 
stage.  158 
 159 
Implementation and simulation of four vaccine characteristics 160 
Vaccine characteristic 1 is simulated by a!reduction in infectiousness of infectious states 161 
towards the sand fly.!For vaccine characteristics 2 and 3, the respective flow towards clinical 162 
VL and PKDL is reduced. With vaccine characteristic 4, we selected 100% development of 163 
transient immunity after having received the vaccine and experimented with vaccinating 164 
100% and 50% of the population. The duration of immunity after vaccination is assumed to 165 
be to 2 years, which is similar to the assumed duration of immunity after natural infection in 166 
our model of which sensitivity analyses are presented in previous work [36]. 167 
 168 
For the simulations of vaccine characteristics, we assume that they apply to everyone 169 
involved, i.e. all ages and sexes. No specific target populations are simulated, besides for 170 
vaccine characteristic 3, which is only administered to those that have developed VL. For 171 
vaccine characteristics 1-3, we assume an arbitrary 50% reduction of the infectiousness as 172 
well as a 50% reduction of the proportions of individuals that develop VL and PKDL, all in 173 
combination with a 100% vaccination coverage. We also calculate the percentage of vaccine 174 
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effectiveness required to achieve the VL elimination target incidence of 1/10,000/year within 175 
10 years of starting the intervention, which could aid in defining a vaccine target product 176 
profile (TPP). We assume that the vaccine characteristics are in place constantly from the 177 
start of the intervention, except for vaccine characteristic 4, where we experiment with 178 
simulating a single vaccination round and repeated yearly vaccination rounds. For all four 179 
vaccine characteristics, we separately simulate and compare their impact on VL incidence 180 
over time, even though it is likely that one vaccine will possess multiple characteristics. The 181 
cumulative effects of some vaccine characteristics are simulated indirectly, as reducing the 182 
development of VL will lead to a decrease in the overall development of PKDL. Previous 183 
work has shown that when current existing interventions have led to the 1/10,000/year target, 184 
there are many susceptible individuals and the infection pressure comes mainly from PKDL 185 
cases (when assuming the infection pressure originates from symptomatic individuals only) 186 
[21]. To address this, we also combine vaccine characteristic 3, vaccination of VL cases to 187 
prevent the development of PKDL, with the current interventions recommended by WHO.  188 
 189 
 190 
Fig 1. Schematic presentation of the model variant in which asymptomatic individuals contribute to transmission, 191 
with numbers related to different types of vaccine characteristics that are implemented in the models. In the 192 
alternative model variant, asymptomatic individuals are assumed not to be infectious towards to sand fly, with infection 193 
pressure only coming from symptomatic individuals with VL (with and without treatment) and PKDL. Once a susceptible 194 
individual is infected by an infectious sand fly, they become early asymptomatic for an average duration of about 200 days, 195 
which is followed by the late asymptomatic stage (average duration of 69 days). The average infectivity of both 196 
asymptomatic stages together is 0 in the model in which they do not contribute and ~1.5% relative to VL in the model in 197 
which they contribute to transmission. 1.4% of late asymptomatic individuals develops VL, and without active case 198 
detection, the duration between onset of symptoms and start of treatment lasts on average 40 days, followed by 1-day 199 
treatment 1 and potentially 28-day treatment 2 or death if left untreated. The average duration of the putatively recovered 200 
stage is 21 months and 5% of these individuals develop PKDL which lasts 5 years on average. The infectivity of PKDL is 201 
90%, relative to VL. The rest recovers to the early recovered stage (average duration of 74 days), followed by the late 202 
recovered stage (average duration of 2 years), which can be interpreted as the duration of immunity. The numbers in the red 203 
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boxes relate to the numbers in the first column of Table 1 and represent the following vaccine characteristics; 1a) early and 204 
late asymptomatic individuals become half as infectious, 1b) all infection states become half as infectious, 2) vaccinated 205 
individuals are 50% less likely to develop symptoms, 3) vaccinated individuals are 50% less likely to develop PKDL, and 4) 206 
vaccinated individuals develop transient immunity against infection.  207 
 208 
 209 
Results 210 
The impact of each of the four vaccine characteristics on VL incidence is illustrated in Fig 2. 211 
A vaccine that reduces infectivity of asymptomatic individuals by 50% (1a) leads to 212 
achievement of the target of less than 1 VL case per 10,000 population per year in about 11 213 
years. When all infected individuals have a reduced infectiousness of 50% (1b), the decline is 214 
steeper, achieving elimination in around 4 years if asymptomatics are the main reservoir of 215 
infection and 11 years when infection is only coming from those with VL and PKDL. 216 
Halving the chance of developing symptoms (2) also has a considerable impact on 217 
transmission, especially if only symptomatic individuals are infective after which elimination 218 
takes about 10 years. However, if most infection pressure arises from asymptomatic 219 
individuals, the impact of halving the development of symptoms will lead to achieving the 220 
elimination target only after about 19 years, when used as a stand-alone tool. A 50% 221 
reduction in the development of PKDL (3), after which not 5% (default) but only 2.5% of 222 
past VL cases develop PKDL, has the smallest impact on transmission. As expected with this 223 
characteristic, the relatively larger impact is seen when only those with VL and PKDL 224 
contribute to transmission, and thus when PKDL plays a more prominent role in the 225 
transmission dynamics. Of all vaccine characteristics, the development of immunity that 226 
protects against infection (as seen in late recovered cases) of the population causes the most 227 
rapid decrease in incidence (4), since the pool of susceptible individuals is completely 228 
removed at once (with the assumption of 100% coverage as used in the model). We 229 
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additionally explored the effect of vaccinating half the population and repeating this yearly 230 
for 5 years in a row (5 x 50%), showing that regular vaccinations are required to sustain the 231 
impact and move towards the low incidence elimination target. 232 
 233 
 234 
Fig 2. The impact of different vaccine characteristics on VL incidence using model variants with and without 235 
asymptomatics contributing to transmission in a setting with a pre-control endemicity of 5/10,000/year. Vaccine 236 
characteristics are in place continuously from year 0 onwards, unless for vaccine characteristic 4, which is administered once 237 
(1 x 100%), or yearly for five years in a row (5 x 50%). The different vaccine characteristics that are also explained in Table 238 
1 and illustrated in Fig 1, are; 1a) early and late asymptomatic individuals become half as infectious, 1b) all infection states 239 
become half as infectious, 2) vaccinated individuals are 50% less likely to develop symptoms, 3) vaccinated individuals are 240 
50% less likely to develop PKDL, and 4) vaccinated individuals become immediately immune. The black dashed line 241 
represents the WHO elimination target of 1/10,000/year. The oscillations in VL incidence are a result of seasonality in the 242 
sand fly density. 243 
 244 
The minimum vaccine effect required for each vaccine characteristic to achieve the VL 245 
elimination target incidence of 1/10,000/year within 10 years of starting the intervention is 246 
presented in Table 2. The vaccine characteristics that impact the development of VL and 247 
PKDL (2 and 3) obviously have a bigger impact in the model in which only VL and PKDL 248 
contribute to transmission.   249 
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Table 2. Minimum required effect of the vaccine characteristics to reach a VL elimination target incidence of 250 
1/10,000/year within 10 years’ time after starting the intervention, when vaccinating 100% of the population in a 251 
setting with a 5/10,000/year pre-control incidence. 252 
 Model variant 
Vaccine characteristic 
Only VL and PKDL 
contribute to transmission 
Asymptomatics are 
main contributors to 
transmission 
1a) required reduction in infectivity of asymptomatic individuals N/A 35% 
1b) required reduction in infectivity of all infected individuals 60% 37% 
2) required reduction in the development of symptoms 56% 68%  
3) required amount of time to reach the elimination target when 
preventing the development of PKDL completely 
11 years >20 years 
4) required minimum number of rounds when vaccinating 50% of 
the susceptible individuals yearly with 100% vaccine efficacy 
14 rounds 5 rounds 
 253 
Vaccine characteristic 3, after which vaccinated individuals are less likely to develop PKDL, 254 
displayed the least impact when used as a stand-alone tool. Fig 3 shows the impact on VL 255 
incidence of a decrease in the development of PKDL of 50% and 100%, combined with the 256 
current interventions for a setting with a pre-control endemicity level of 5/10,000/year. The 257 
red line represents the default scenario in which the current interventions (active case 258 
detection and vector control) are in place during the WHO attack phase (year 0—5) and the 259 
WHO consolidation phase (year 5—10), without the presence of a vaccine. Further details on 260 
the impact of current interventions on VL incidence on the ISC as predicted by these models 261 
can be found in Le Rutte et al., 2018 [21]. After halting all interventions at year 10, the 262 
situation will slowly return to the pre-control equilibrium of 5/10,000/year, because of the 263 
remaining VL incidence in year 10 in all scenarios. In the two scenarios with the PKDL 264 
vaccine (green and blue lines) a new, much lower, equilibrium will be reached after regular 265 
interventions are halted. For the vaccine with a 50% efficacy (50% decrease in PKDL 266 
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development of vaccinated VL cases) the target of 1/10,000/year will be reached as simulated 267 
by the model in which only VL and PKDL contribute to transmission. When assuming an 268 
effect of 100% protection from developing PKDL, this model suggests that using only 269 
vaccine 3 could keep the incidence below 1/10,000/year, after all regular interventions have 270 
brought incidence down and are halted. However, in settings with a higher pre-control 271 
endemicity of 10/10,000/year, only the vaccine with 100% protection against development of 272 
PKDL will lead to the elimination target of VL after 15-20 years depending on the start year 273 
of the PKDL vaccine.  274 
 275 
Fig 3. Strategies of combining vaccine effect 3 with the WHO attack and consolidation phase for a setting with a pre-276 
control endemicity level of 5/10,000/year. Top panels: vaccine effect with 100%!protection against the development of 277 
PKDL, bottom panels: vaccine effect with 50% protection against the development of PKDL. The default strategy is 278 
visualized with the red line (top and bottom row identical), in which 5 years of attack phase are followed by 5 years of 279 
consolidation phase, after which interventions are halted in year 10. For the green line, the PKDL vaccine is introduced 280 
during the consolidation phase (year 5), which continues after the consolidation phase has ended at year 10. For the blue 281 
line, the PKDL vaccine is already introduced at the start of the attack phase (year 0), continues during the consolidation 282 
phase and is continued when regular interventions are halted in year 10. Left figures show the simulations for the model 283 
variant where solely symptomatic individuals contribute to transmission, whereas for the right figures asymptomatic 284 
individuals constitute the main reservoir of infection. The black dashed line represents the WHO VL incidence target of 285 
1/10,000/year. The oscillations in VL incidence are a result of seasonality in the sand fly density. 286 
 287 
 288 
Discussion 289 
In this study, we present for the first time the potential impact of VL vaccines on 290 
transmission dynamics and population incidence on the Indian subcontinent (ISC). This 291 
impact looks very promising. We found that all simulated vaccine characteristics show 292 
potential in reducing population VL incidence, particularly those that reduce the infected 293 
individual’s infectiousness or reduce the chance of developing symptoms once infected. For 294 
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these vaccines, an approximate 60% vaccine efficacy would lead to achieving the ISC 295 
elimination target (<1 VL case per 10,000 population per year) within 10 years’ time in a 296 
moderately endemic setting, assuming that the entire population is vaccinated and only VL 297 
and PKDL cases contribute to transmission. For the model variant in which asymptomatics 298 
are the main contributors to transmission, much lower vaccine efficacies of around 37% 299 
would be required when reducing the infectiousness; however, for the required reduction in 300 
the development of symptoms, a vaccine efficacy of nearly 70% was estimated. The vaccine 301 
that leads to immunity akin to that of late recovered cases shows the highest impact, but 302 
individuals would require regular booster vaccines to achieve and sustain the low incidence 303 
elimination target. Vaccinating VL cases to prevent the development of PKDL shows to be a 304 
promising tool to sustain the elimination target once reached, and prevent recrudescence of 305 
infection when regular interventions are halted. Those findings are of great importance in 306 
providing a factual base to the ongoing effort aimed at establishing a TPP for a VL vaccine. !307 
!308 
A limitation to our study is the fact that we simulated vaccine characteristics rather 309 
simplistically by instantaneously altering the transition rates and applying this simultaneously 310 
to all individuals in the population. Ideally, vaccinated individuals should move to different, 311 
additional, compartments in the model, where they experience a different history of infection. 312 
In such a model, vaccinated and unvaccinated individuals would be living beside each other, 313 
both influencing the transmission dynamics differently, although the outcomes would likely 314 
only differ quantitatively with ours. Another limitation of our study is that we only present 315 
the results for a setting with a pre-control endemicity of 5 VL cases per 10,000 population per 316 
year, which we considered representative for endemic situations where vaccines would be 317 
most useful. In settings with a lower pre-control endemicity the elimination target would be 318 
achieved earlier; in settings with a higher pre-control endemicity, the vaccine characteristics 319 
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would require a higher efficacy to achieve the same effect on VL incidence in the same 320 
amount of time.  321 
 322 
We further decided to simulate the vaccine characteristics separately, while in reality most 323 
vaccines are expected to possess multiple characteristics. For example lowering the parasite 324 
load will likely lead to both decreased infectiousness as well as reduced development of 325 
symptoms, as is also seen in canine VL vaccines [12,13]. However, by combining them it 326 
would be less clear to what extent different characteristics would drive the total impact of a 327 
vaccine. For the vaccine that causes vaccinated individuals to develop transient immunity 328 
against infection, it is important to note that the impact on VL incidence, as well as the 329 
required number of booster vaccines, highly depends on the duration of acquired immunity, 330 
which was assumed to be two years on average in our models similar to what we used in 331 
previous work [36]. The longer the duration of acquired immunity, the bigger the impact on 332 
VL incidence and the lower the frequency of required booster vaccines. We also assume that 333 
for all vaccine characteristics the efficacy is 50%. Even though this is a generalization and in 334 
reality it is likely different for each characteristic, this approach allows us to compare the 335 
impact of the different vaccine characteristics. In	this	study	we	simulate	transmission	336 
between	humans	and	sand	flies,	which	is	currently	considered	to	reflect	the	337 
transmission	dynamics	of	VL	on	the	ISC. However, would	a	considerable	contribution	to	338 
transmission	come	from	an	animal reservoir, vertical transmission as seen in dogs, and/or 339 
the	presence	of those with HIV-VL	co-infection, the	potential	impact	of	vaccines	could	340 
increase	[13,39–41]. 341 
A typical aspect of the deterministic model that we use is that all durations of states are 342 
exponentially distributed, which often does not reflect the actual distributions of durations as 343 
found in nature. The slow recrudescence of infection between year 10 and 20 is another 344 
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phenomenon of the deterministic model, where prevalences can never become completely 345 
zero, but in reality the disease will either die out or come back, and if it comes back, most 346 
likely it will progress somewhat faster. Around the elimination target when numbers of 347 
infected cases become very low, the role of chance increases and a stochastic transmission 348 
model would be required to analyse the risks of recrudescence or the chance of achieving 349 
(local) elimination of transmission. 350 
 351 
We acknowledge that some of the assumptions chosen for the simulation are not fully 352 
reflective of the reality of implemented immunization programs. Firstly, our choice of 100% 353 
coverage certainly is an overestimation of what can be realistically achieved. For example, 354 
coverage for the 1st dose of measles-containing vaccines was on average 73% in the AFRO 355 
region, and the human papilloma virus vaccination had an average coverage of 88% when 356 
pooling regions and income levels [42,43]. However, this assumption allowed us to evaluate 357 
the maximum impact and to do such an evaluation independently from the constraints of 358 
delivery strategy. Also, having chosen another coverage level would not alter our outcomes 359 
when comparing the impact of the different characteristics. With a lower coverage, the 360 
durations until elimination as a public health problem would be longer and the minimum 361 
required efficacies would be higher. Secondly, and in particular at the start of vaccination 362 
programs, a catch up campaign is usually implemented to quickly reduce the susceptible 363 
population, focusing on the population that is at highest risk (i.e. for leishmaniasis, children 364 
and young adults or migrant workers [44]). Such programmatic design considerations are not 365 
considered in the current model and will need to be investigated with more complex 366 
individual-based transmission models. Lastly, 5-year protection is most likely going to be the 367 
minimum requirement to allow for a widespread roll-out in routine immunization. Shorter 368 
durations requiring a very frequent administration of booster doses might prove 369 
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programmatically and financially unsustainable. Nevertheless, from an impact assessment 370 
standpoint the results generated with the more conservative assumptions of the current model 371 
have clear significance for understanding the relative importance of different vaccine 372 
characteristics. 373 
 374 
Vaccines have proven to be vital tools in the control and prevention of diseases [45,46]. This 375 
study reveals that a VL vaccine strategy could also prove an important tool in the fight 376 
against this neglected tropical disease. We focussed on the anthroponotic transmission 377 
dynamics of VL on the Indian subcontinent, but also in the rest of the world VL vaccines are 378 
likely to surpass their impact at the patient level by reducing the infection pressure, positively 379 
impacting the estimated 6 million people at risk of VL globally [47].  380 
 381 
In conclusion, even though VL vaccines are not yet available for implementation, our results 382 
strongly support their continued development, given the potentially substantive impact on 383 
transmission, decreasing incidence at the population level, and sustaining the low incidence 384 
elimination target on the ISC when other interventions are relaxed.  More details of the 385 
impact of different vaccines characteristics on the history of infection are awaited to further 386 
our understanding and modelling of the impact of VL vaccines on VL transmission dynamics 387 
and disease incidence. 388 
 389 
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